Cardiovascular Patient Articles & Analysis
70 news found
The study adds to the evidence obtained in the randomized controlled ROCKET-AF study and supports the use of Xarelto in this patient group, including the cautious use for patients with CKD stage 4 (the use of Xarelto is not recommended in patients with creatinine clearance < 15 ml/min). ...
ByBayer AG
“Patients with chronic kidney disease are faced with an increased risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...
ByBayer AG
This therapeutic option has shown one of the strongest launch dynamics in the US market, outperforming benchmark launches in the cardiovascular space. This strong launch momentum is expected to continue, driven by its robust position on top of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, its broad utility and relevance across general practitioners, ...
ByBayer AG
The study demonstrated that finerenone reduced the risk of cardiovascular events in a broad population of patients with stages 1-4 CKD and T2D. ...
ByBayer AG
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional ...
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are ...
Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). Fu rthermore, patients with homozygous familial hypercholesterolemia who have markedly ...
Abstract Project Summary Abstract The epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of ...
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. ...
” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...
Wayne Miller, Mayo Clinic, cited data from this study and concluded that “there are limitations to the use of the surrogates, if you need to know information about volume [in heart failure patients], you need to measure volume.” The study titled, “Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients with Worsening ...
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier ...
Patients living with chronic kidney disease associated with type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...
ByBayer AG
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its ...
ByBayer AG
XFLO offers a reversible and office-based treatment option for patients who are seeking immediate relief from lower urinary tract symptoms (LUTS) caused by BPH without compromising sexual function. ...
The chief technician of BOC Sciences expatiates some information about C-peptide as an example, "Our C-peptide can alleviate and delay the occurrence and development of chronic complications such as kidney, nerve, and cardiovascular in patients with type 1 diabetes by activating some enzymes, which provides a new solution to the treatment of type 1 diabetes." ...
“As a thought leader in cardiovascular medicine and a foremost expert in CT angiography, his extensive experience in cardiovascular disease assessment will be an invaluable asset for Elucid and his contributions will substantially impact patient care globally. ...
ByElucid
The last patient was enrolled in May 2022. “I am deeply impressed by the accuracy and quick learning curve of R-One. ...
ByRobocath
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. ...
ByBayer AG
“Patients with refractory angina have no treatment options, and the results from the Phase 1 portion of the EXACT trial suggest a dose response and therapeutic potential which is encouraging for the development of XC001 as a treatment to improve these patients’ quality of life. ...